Celldex Therapeutics, Inc. — Director's Dealing 2019

Jun 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2019-06-19

Reporting Person: Martin Samuel Bates (SVP and CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-19	Incentive Stock Option (right to buy)	$2.78	A	43000	Acquired	2029-06-19	Common Stock (43000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2: 25% vest on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.